FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab 17 במאי 2018 מחקר FRAME קרא עוד ←
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis 12 באוקטובר 2017 מחקר ARCH קרא עוד ←
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial 30 בספטמבר 2017 מחקר Structure קרא עוד ←
